Paris start­up col­lects €27M in Se­ries B to ad­vance over­ac­tive blad­der treat­ment

A French biotech fo­cused on de­vel­op­ing ge­net­ic med­i­cines for neu­ro­log­i­cal con­di­tions has se­cured €27 mil­lion in a Se­ries B raise to sup­port its lead pro­gram …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER